400-920-2911 sales@csnpharm.cn
货号 | 产品名 | CAS号 | 信息 |
---|---|---|---|
CSN21175 | (1S,2S)-2-PCCA | 1609624-97-6 | (1S,2S)-2-PCCA is a less active diastereomer of 2-PCCA. 2-PCCA is a GPR88 agonist, and inhibits GPR88-mediated cAMP production, with an EC50 of 116 nM in HEK293 cells. |
CSN21333 | Adenosine antagonist-1 | 431040-19-6 | Adenosine antagonist-1 is an adenosine A3 receptor (AA3R) antagonist. |
CSN21281 | S 38093 | 862896-30-8 | S 38093 is a brain-penetrant antagonist/inverse agonist of H3 receptors. |
CSN21251 | Gcase activator 1 | 1919820-28-2 | LTI-291, a extract from patent WO 2017192841 A1, is an activator of glucocerebrosidase (Gcase) for treatment of Parkinson's disease. |
CSN21228 | CB2R-IN-1 | 1257555-79-5 | CB2R-IN-1 is a potent cannabinoid CB2 receptor inverse agonist with a Ki of 0.9 nM. |
CSN21180 | VU0467154 | 1451993-15-9 | VU0467154 is a positive allosteric modulator of the M4 muscarinic acetylcholine receptor (mAChR), potentiating the response to ACh with pEC50s of 7.75, 6.2 and 6 for rat, human and cynomolgus monkey M4 receptor, respectively. |
CSN21275 | NHE3-IN-1 | 632355-68-1 | NHE3-IN-1 is a sodium/proton exchanger type 3 (NHE-3) inhibitor extracted from patent WO 2011019784 A1. |
CSN21141 | LY334370 | 182563-08-2 | LY 334370 is a selective 5-HT1F receptor agonist (Ki=1.6nM). LY 334370 HCl displays antimigraine effects. |
CSN21174 | (1R,2R)-2-PCCA HCl | 1609563-71-4 | (1R,2R)-2-PCCA hydrochloride is a diastereomer of 2-PCCA, and acts as a potent GPR88 agonist, with an EC50 of 3 nM. |
CSN21328 | UK-240455 | 178908-09-3 | UK-240455 is a potent and selective N-methyl D-aspartate (NMDA) glycine site antagonist. |
CSN21178 | CGP52432 | 139667-74-6 | CGP52432 is an antagonist of GABAB receptor with an IC50 of 85 nM. |
CSN21287 | 4-Oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate | 877636-42-5 | ML221 is a potent apelin receptor (APJ) antagonist with IC50s of 0.70 μM and 1.75 μM in cAMP and β-arrestin assay respectively. |
CSN21265 | LX2343 | 333745-53-2 | LX2343 is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive PI3K inhibitor with an IC50 of 15.99±3.23 μM. LX2343 stimulates autophagy in its promotion of Aβ clearance. |
CSN21214 | PZM21 | 1997387-43-5 | PZM21 is a potent and selective μ opioid receptor agonist with an EC50 of 1.8 nM. |
CSN21196 | GENZ-882706 | 2070864-35-4 | GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) inhibitor that intends to treat immune-mediated diseases and neurological diseases. |
CSN21258 | Tecadenoson | 204512-90-3 | Tecadenoson is a selective A1 adenosine receptor agonist. |
CSN21285 | Revefenacin | 864750-70-9 | TD-4208 is a long-actingmuscarinic cholinergic receptor (mAChR) antagonist and may be potentially useful for the treatment of respiratory disease. |
CSN21219 | UCPH-101 | 1118460-77-7 | UCPH 101 selectively but not competitively inhibit excitatory amino acid transporter 1 (EAAT1) with IC50 of 660 nM. It exhibits relatively weak inhibition of other subtypes. |
CSN21278 | Methiothepin mesylate | 74611-28-2 | Methiothepin mesylate is a potent and non-selective 5-HT2 receptor antagonist, with pKds of 7.10 (5-HT1A), 7.28 (5HT1B), 7.56 (5HT1C), 6.99 (5HT1D), 7.0 (5-HT5A), 7.8 (5-HT5B), 8.74 (5-HT6), and 8.99 (5-HT7), and pKis of 8.50 (5HT2A), 8.68 (5HT2B), and 8.35 (5HT2C). |
CSN21286 | Varenicline 2HCl | 866823-63-4 | Varenicline HCl is a nicotinic receptor partial agonist and it stimulates nicotine receptors more weakly than nicotine itself does. |
CSN21167 | Aftin-4 | 866893-90-5 | Aftin-4 is a potent and selective Aβ42 inducer with an EC50 of 30 μM. |
CSN21170 | 2-Pcca | 1984859-71-3 | 2-PCCA is a racemic form of the GPR88 agonist, and inhibits GPR88-mediated cAMP production, with an EC50 of 116 nM in HEK293 cells. |
CSN21312 | SX-3228 | 156364-04-4 | SX-3228 is a selective benzodiazepine1 (BZ1) receptor agonist with an IC50 of 17 nM. |
CSN21326 | Dimetacrine | 4757-55-5 | Dimetacrine is a useful antidepressant which can be used for the treatment of various types of depression. |
CSN21310 | 5-HT1A modulator 1 | 142477-34-7 | 5-HT1A modulator 1 displays very high affinities for the 5HT1A, adrenergic α1 and dopamine D2 receptor with IC50s of 2 ±0.3 nM, 10 ± 3 nM and 40 ±9 nM, respectively. |
CSN21116 | Salsolidine | 5784-74-7 | Salsolidine is a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A inhibitor. |
CSN21189 | 4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine | 566169-98-0 | 4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine is a potent amyloid imaging agent which binds to Amyloid-β (1-40) with a KD of 1.7 nM. |
CSN21173 | 2-PCCA hydrochloride | 1609563-70-3 | (1S,2S)-2-PCCA HCl is a less active diastereomer of 2-PCCA. 2-PCCA is a GPR88 agonist, and inhibits GPR88-mediated cAMP production, with an EC50 of 116 nM in HEK293 cells. |
CSN21120 | MDR-1339 | 1018946-38-7 | DWK-1339 is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease. |
CSN21171 | 2-PCCA HCl | N/A | 2-PCCA HCl is a GPR88 agonist, and inhibits GPR88-mediated cAMP production, with an EC50 of 116 nM in HEK293 cells. |
CSN21321 | MK-3328 | 1201323-97-8 | MK-3328 is a β-Amyloid PET ligand, which exhibits high binding potency with an IC50 of 10.5 nM. |
CSN21136 | Methylbenactyzium Bromide | 3166-62-9 | Methylbenactyzium Bromide is a mAchR antagonist, used as a spasmolytic for the treatment of gastrointestinal ulcer and gastrointestinal spasms. |
CSN21125 | Ibotenic acid | 2552-55-8 | Ibotenic acid has agonist activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Qm) receptor sites. |
CSN21074 | Blarcamesine HCl | 195615-84-0 | σ1 agonist (IC50 = 860 nM); also displays affinity for muscarinic M1-M4 receptors (Ki values < 500 nM), but not for σ2 receptors. Exhibits neuroprotective effects, prevents tau hyperphosphorylation, and attenuates scopolamine- and (+)-MK 801-induced learning deficits in a mouse model of amyloid toxicity. |
CSN22118 | Sultopride HCl | 23694-17-9 | Sultopride HCl is a selective antagonist of dopamine D2 receptor |
CSN22123 | ZD7288 | 133059-99-1 | ZD7288 is a selective hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker. |
CSN22139 | Cipralisant | 213027-19-1 | Cipralisant is a potent and selective histamine H3 receptor antagonist in vivo, and an agonist in vitro, with a pKi of 9.9 for histamine H3 receptor and a Ki of 0.47 nM for rat histamine H3 receptor; Cipralisant has entered in clinical trials for the treatment of attention-deficit hyperactivity disorder. |
CSN22137 | tCFA15 | 220757-88-0 | tCFA15 is a trimethyl cyclohexenonic long chain fatty alcohol containing 15 carbon atoms on the side chain, promotes the differentiation of neurons, and may regulates Notchsignaling. |
CSN22143 | ERB-196 | 550997-55-2 | ERB-196 is a nonsteroidal selective estrogen receptor-β (ERβ) agonist. |
CSN20672 | Aripiprazole Lauroxil | 1259305-29-7 | Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic. It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to six weeks for the treatment of schizophrenia. |
CSN21376 | AM-0902 | 1883711-97-4 | Potent and selective TRPA1 antagonist (IC50 = 0.02 μM for human TRPA1). Exhibits no siginificant activity against human TRPV1 or TRPV4, and rat TRPV1, TRPV3 or TRPM8. Exhibits efficacy in a rat pain model. Orally bioavailable. |
CSN21070 | CP-609754 | 1190094-64-4 | CP-609754, also known as CP-609,754, LNK 754 and OSI 754, is a selective inhibitor of arnesyltransferase with potential anticancer activity. |
CSN21413 | RG7800 HCl | N/A | RG7800 HCl is an orally active SMN2 splicing modulator, with EC1.5xs of 23 nM and 87 nM for SMN2 splicing and SMN protein; has the potential to treat spinal muscular atrophy. |
CSN21372 | PF-06751979 | 1818339-66-0 | PF-06751979 is a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 7.3 nM in BACE1 binding assay. |
CSN21373 | Risdiplam | 1825352-65-5 | Risdiplam is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels. |